Prescient Therapeutics (FRA:UDD) Current Accrued Expense: €0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Prescient Therapeutics Current Accrued Expense?

Prescient Therapeutics FRA:UDD -37.25% Current Accrued Expense is €0.00 Mil as of Jun. 2026. The stock has 1 warning sign investors should review.

Prescient Therapeutics's Current Accrued Expense for the quarter that ended in Jun. 2026 was €0.00 Mil.

Prescient Therapeutics Current Accrued Expense Related Terms

Prescient Therapeutics Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Prescient Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prescient Therapeutics Current Accrued Expense Chart

Prescient Therapeutics Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Prescient Therapeutics Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Prescient Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of €0.00 Mil mean?
Prescient Therapeutics (FRA:UDD) has a Current Accrued Expense of €0.00 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Prescient Therapeutics and its competitors.
Is Prescient Therapeutics' Current Accrued Expense too high?
Prescient Therapeutics' current Current Accrued Expense is €0.00 Mil.
How does Prescient Therapeutics' Current Accrued Expense compare to VRTX and REGN?
Prescient Therapeutics' Current Accrued Expense of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Prescient Therapeutics and its competitors. Prescient Therapeutics's current Current Accrued Expense is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prescient Therapeutics stock overvalued right now?
Prescient Therapeutics (FRA:UDD) has a current Current Accrued Expense of €0.00 Mil. The current Current Accrued Expense is €0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Prescient Therapeutics (FRA:UDD), the current Current Accrued Expense is €0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Prescient Therapeutics Business Description

Other Exchanges PTX:Australia
Address 385 Bourke Street, Suite 2, Level 11, Melbourne, VIC, AUS, 3200
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.